（文章来源：证券日报） 证券日报网讯 8月5日晚间，爱尔眼科发布公告称，公司2025年第二次临时股东大会审议通过了《关于 部分募投项目结项并将节余募集资金永久补充流动资金的议案》。 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-055 爱尔眼科医院集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第二次临时 股东大会采用现场表决与网络投票相结合的方式召开。其中，通过深圳证券交易 所交易系统进行网络投票的时间为：2025 年 8 月 5 日 9:15 至 9:25、9:30 至 11:30， 13:00 至 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 5 日 9:15 至 15:00 期间的任意时间；现场会议于 2025 年 8 月 5 日 14:30 在长沙市芙蓉南路一段 188 号爱尔大厦 B1 层国际会议厅召开。本次股东大会由 公司董事会召集，副董事长李力先生主持，公司董事、监事、高级管理人员、律 师等相关人士出席了本次会议。会议的召集、召开 ...

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2025年第二次临时股东大会的 法律意见书 二零二五年八月五日 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限 公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第二次临时 股东大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、 出席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 （二）本所律师遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对 本法律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证 本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准 确，不存在虚假记载、误导性陈述或者重大遗漏。 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本法律意见，本所律师依法查验了公司提供的下列资料： 1、刊登在深圳证券交易所网站（http://www.szse.cn/）的与本次股东大会有 关的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、授权委托书等； 本所 ...

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Group 1 - The core viewpoint is that the liquidity and fundamentals of the Chinese healthcare industry continue to improve, maintaining a positive outlook for the healthcare sector [1] - The report indicates that the weak U.S. employment data may lead to heightened expectations for monetary easing in the second half of the year, suggesting an improved outlook for the industry [1] - The report highlights that the industry fundamentals are recovering, with a month-on-month increase in hospital prescription volumes in July, and significant profit growth expected in the third quarter due to the release of more innovative drugs [1] Group 2 - The company prefers leading large pharmaceutical firms and suggests avoiding companies overly reliant on biosimilars in the short term [2] - Selected stocks include: CSPC Pharmaceutical Group (01093), Sinopharm Group (01099), Hansoh Pharmaceutical (03692), and others [2] - The report emphasizes that the uncertainty in U.S. Treasury yields may prompt a reallocation of funds, further improving the liquidity of innovative drug assets [1]

里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...

Core Viewpoint - The first "Excellent Cases of ESG Practices by Enterprises in the Yangtze River Economic Belt" conference highlighted the importance of ESG (Environmental, Social, and Governance) as a key evaluation system for sustainable development, emphasizing its role in reshaping corporate value and driving industrial transformation [3][4]. Group 1: ESG Policy and Development - Recent years have seen a surge in ESG policies in China, with the Shanghai and Shenzhen Stock Exchanges set to enforce mandatory disclosure of sustainability reports starting April 2024, prioritizing climate change responses [3]. - The Ministry of Finance has integrated climate-related content into its guidelines, aligning with the national "dual carbon" goals [3]. - The State-owned Assets Supervision and Administration Commission has issued guidelines for central enterprises to fulfill social responsibilities, with local state-owned asset management offices also releasing related opinions [3]. Group 2: Corporate Participation and Innovation - Enterprises along the Yangtze River Economic Belt are accelerating their transformation towards a green economy, becoming a key battleground for ecological priority and green development in China [3]. - A diverse group of nearly 100 representatives from central and local state-owned enterprises, as well as large private companies, gathered to discuss innovative approaches to sustainable development and the integration of ESG principles [4]. - The conference featured 45 companies recognized for their outstanding ESG practices in 2024, showcasing their innovative measures through video presentations [5].

Core Viewpoint - Aier Eye Hospital's stock price showed a slight increase, reflecting stable market performance amid significant shareholder activities and upcoming corporate governance decisions [1]. Company Overview - Aier Eye Hospital is a leading ophthalmology medical chain in China, providing services in refractive surgery, cataract treatment, and optometry [1]. - In Q1 2025, the company reported revenue of 6.026 billion yuan and a net profit attributable to shareholders of 1.05 billion yuan [1]. Shareholder Activities - The company's actual controller, Chen Bang, pledged 139 million shares, accounting for 9.63% of his holdings, while also unpledging 183 million shares [1]. - As of the announcement date, Chen Bang has a total of 212 million pledged shares, representing 2.27% of the company's total share capital [1]. Upcoming Corporate Actions - A temporary shareholders' meeting is scheduled for August 5 to discuss the completion of certain fundraising projects and the allocation of surplus funds to supplement working capital [1]. Market Activity - On August 4, the main funds experienced a net outflow of 33.0386 million yuan, with a cumulative net outflow of 2.41 billion yuan over the past five days [1].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 2.95% increase in the biopharmaceutical sector while the total A-share market declined by 1.01% [28][4]. - The report highlights significant advancements in Alzheimer's disease treatments presented at the 2025 AAIC conference, with multiple drugs updating their clinical research data [11][5]. - Roche's Trontinemab, a new generation Aβ antibody, demonstrated a 91% clearance rate of Aβ plaques in high-dose groups during Phase 1b/2a trials, indicating promising safety and efficacy [2][12]. Market Performance - The overall A-share market decreased by 1.01%, while the biopharmaceutical sector increased by 2.95%, with chemical pharmaceuticals leading with a 5.01% rise [28][4]. - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 39.10x, which is at the 80.69th percentile of its historical valuation over the past five years [33][4]. Key Companies and Investment Ratings - Mindray Medical (300760.SZ): Outperform, market cap 275.5 billion, projected net profit for 2024A is 11.67 billion [4]. - WuXi AppTec (603259.SH): Outperform, market cap 267 billion, projected net profit for 2024A is 9.35 billion [4]. - New Industries (300832.SZ): Outperform, market cap 42.6 billion, projected net profit for 2024A is 1.83 billion [4]. - Huatai Medical (688617.SH): Outperform, market cap 39.4 billion, projected net profit for 2024A is 670 million [4]. - Aier Eye Hospital (not listed): Outperform, focusing on rapid expansion in the ophthalmology service sector [37]. Clinical Research Developments - Trontinemab's Phase 1b/2a study showed significant reductions in Aβ plaque levels, with the 3.6 mg/kg dose group achieving a mean reduction from 119 CL to 21 CL after 12 weeks [14][12]. - The report emphasizes the strategic focus of overseas pharmaceutical companies on CNS (central nervous system) drug development, particularly in Alzheimer's treatments [2][25]. Recommendations - The report suggests monitoring the domestic and international AD detection and treatment drug-related industry chain, highlighting the potential for growth in this area [2][25].

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-054 爱尔眼科医院集团股份有限公司 关于公司实际控制人进行股票质押式回购交易及部分股份 解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或者重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）近日接到公司实际控 制人陈邦先生函告，获悉陈邦先生所直接持有本公司的部分股份进行股票质押式 回购交易及部分股份解除质押，具体事项如下： 一、股东股份质押及解除质押的基本情况 | 股东 | 是否为 控股股 东或第 一大股 | 本次质押 | 占其所 持股份 | 占公 司总 | 股份性质 | 是否 为补 | 质押起 | 质押到期 | 质权人 | 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其 | 股数（股） | 比例 | 股本 比例 | | 充质 押 | 始日 | 日 | | | | | 一致行 动人 | | | | | | | | | | | | | | | | | | | | 华泰证 ...